Analyst Stan Berenshteyn from Wells Fargo reiterated a Buy rating on Healthequity and keeping the price target at $125.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Stan Berenshteyn’s rating is based on several positive developments for Healthequity. The company reported a strong third quarter with revenues and adjusted EBITDA exceeding expectations, indicating robust operational performance. The guidance for fiscal year 2026 has been raised, reflecting confidence in continued growth, although the revised outlook remains conservative.
Additionally, Healthequity is experiencing record growth in Health Savings Account (HSA) memberships, driven by conversions from the Affordable Care Act (ACA) and new marketplace monetization strategies. The company’s progress in securing forward contracts and expanding service margins further supports its growth potential. The initial success in the marketplace, particularly with GLP-1s, and the potential for significant customer acquisition from ACA exchanges, add to the long-term growth narrative. These factors collectively underpin Berenshteyn’s Buy rating for Healthequity’s stock.
Berenshteyn covers the Healthcare sector, focusing on stocks such as Healthequity, Veeva Systems, and Doximity. According to TipRanks, Berenshteyn has an average return of -7.5% and a 50.45% success rate on recommended stocks.
In another report released on December 1, RBC Capital also maintained a Buy rating on the stock with a $110.00 price target.